NCT02074839 2025-06-08Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationServierPhase 1 Recruiting291 enrolled 3 FDA
NCT02081378 2024-03-18A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALLNovartisPhase 1 Completed326 enrolled 1 FDA
NCT02561988 2023-03-17(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesBlueprint Medicines CorporationPhase 1 Completed86 enrolled 1 FDA